Latest:
Dr. Pegram on the Evolving Treatment Landscape in HER2+ Breast Cancer
Mark Pegram, MD, discusses the evolving treatment landscape of HER2-positive breast cancer.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Nilo Azad, MD
Latest:
Dosing Trifluridine-Tipiracil (TAS-102) Plus Bevacizumab Considerations: Hepatic or Renal Impairment
Panelists discuss the frequency of hypertension observed with trifluridine-tipiracil plus bevacizumab and their strategies for monitoring and managing it, as well as their approach to dosing TAS-102 plus bevacizumab in patients with hepatic or renal impairment. They also review common toxicities associated with fruquintinib and regorafenib, including hypertension, hand-foot syndrome, and hepatotoxicity, and share management strategies for these adverse events.
Srinivas K. Tantravahi, MBBS, MRCP
Latest:
Dr Tantravahi on the Efficacy of Selinexor Plus Ruxolitinib in JAK Inhibitor–Naive Myelofibrosis
Srinivas K. Tantravahi, MBBS, MRCP, discusses the preliminary efficacy of selinexor in combination with ruxolitinib in patients with JAK inhibitor–naive myelofibrosis, as seen in the phase 1 XPORT-MF-034 trial.
Tsewang Tashi, MD
Tsewang Tashi, MD, is a hematologist/oncologist and an associate professor in the Division of Hematology & Hematologic Malignancies at the University of Utah Huntsman Cancer Institute and leader of the Mastocytosis Program at the Huntsman Cancer Hospital
Latest:
Dr Tashi on Differentiating Characteristics of Elenestinib in Indolent Systemic Mastocytosis
Tsewang Tashi, MD, discusses the aspects of elenestinib that differentiate it from avapritinib in the management of indolent systemic mastocytosis.
Rylan DeStefano
Latest:
Acimtamig Plus Allogeneic Natural Killer Cells Under Phase 2 Evaluation in R/R Hodgkin Lymphoma and CD30+ PTCL
Following promising preclincial findings, acimtamig plus allogenic natural killer cells will be examined for the treatment of patients with relapsed/refractory Hodgkin lymphoma and CD30-positive peripheral T-cell lymphoma.
Alexander Chehrazi-Raffle, MD
Alexander Chehrazi-Raffle, MD, is an assistant professor in the Department of Medical Oncology & Therapeutics Research at City of Hope.
Latest:
Dr Chehrazi-Raffle on the TiNivo-2 Study of Tivozanib With/Without Nivolumab in mRCC
Alexander Chehrazi-Raffle, MD, discusses the rationale for a subgroup analysis of the TiNivo-2 of tivozanib with/without nivolumab in mRCC.
Cesar Rodriguez, MD
Latest:
EHA 2025 Insights: Emerging Developments and Future Perspectives for the Multiple Myeloma Treatment Landscape
Panelists discuss how emerging combination therapies such as bispecific antibodies with chimeric antigen receptor (CAR) T cells show promising response rates in patients with heavily refractory disease, while highlighting the ongoing unmet need to improve treatment access and educate community practices on advanced therapies.
Xingming Zhang
Latest:
Dr Zhang on the Rationale for Investigating Sintilimab/Axitinib in FH-Deficient RCC
Xingming Zhang, MD, discusses the rationale for investigating the combination of sintilimab and axitinib in patients with advanced fumarate hydratase-deficient renal cell carcinoma in a phase 2 trial.
Tarek Mouhieddine, MD
Tarek Mouhieddine, MD, is a medical oncologist at Dana-Farber Cancer Institute and an instructor in medicine at Harvard Medical School.
Latest:
Dr Mouhieddine on Future Directions With Ferritin and ALC as Biomarkers in Myeloma
Tarek Mouhieddine, MD, discusses future research directions with ferritin and ALC as biomarkers of response to bispecific antibodies in myeloma.
Shiruyeh Schokrpur, MD, PHD
Latest:
PD-L1 Status Stratifies Immunotherapy Treatment in NSCLC
Data from completed studies evaluating immunotherapy in lung cancer alone or in combination with chemotherapy show that a breakdown of populations by PD-L1 status and additional considerations such as toxicity profiles should guide treatment decisions.